

## Valens™ Vaccine Adjuvants and Biologics

### Valens™ T4Q: TLR4 Agonist & QS-21 Adjuvant System



Valens™ T4Q adjuvant system is an adjuvant system combining Inimmune's novel fully synthetic TLR4 agonist INI-2002 with the saponin adjuvant QS-21 from SPI Pharma. Valens™ T4Q offer advantages over current clinical adjuvants including improved availability, stability, and production sustainability. INI-2002 alone offers greatly improved stability compared to current clinical TLR4 adjuvants. Additionally, we have developed an innovative formulation approach that avoids the cold chain requirement of current clinical TLR4 + Saponin adjuvant combinations.

In July 2024, SPI Pharma and Inimmune Corp announced a partnership to develop and commercialize this innovative adjuvant system.

#### Efficacy in Pre-Clinical Models

- T4Q demonstrates comparable or improved immunogenicity compared to current clinical TLR4 + Saponin adjuvant combinations.
- Corresponding or improved injection site pain compared to current clinical TLR4 + Saponin adjuvant combinations depending on the formulation of T4Q that is being investigated.
- T4Q adjuvanted vaccines are efficacious in pre-clinical influenza challenge models.

#### cGMP Manufacturing

- INI-2002 has been manufactured under cGMP conditions.
- T4Q cGMP manufacturing is in progress.

SPI Pharma, as the commercial partner, can assist you with Inimmune's expertise to help develop vaccines readily and easily from our T4Q platform. Please contact SPI Pharma to discuss your needs further, including T4Q samples and relevant data.

[www.spipharma.com](http://www.spipharma.com) • [salesinfo@spipharma.com](mailto:salesinfo@spipharma.com)



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.